Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
brontictuzumab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Brontictuzumab and trifluridine/tipiracil | EXPERIMENTAL | Brontictuzumab will be administered per protocol and trifluridine/tipiracil per label. |
| Name | Type | Description |
|---|---|---|
| brontictuzumab | DRUG | starting dose of 1.5mg/kg administered intravenously (IV) |
| trifluridine/tipiracil | DRUG | - |
Inclusion Criteria: * Histologically confirmed metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if KRAS wild-type, an anti-EGFR therapy * ECOG performance status 0 or 1 Exclusion Crit...
Top 20 of 77 competitors
Brontictuzumab is an investigational drug being studied for the treatment of metastatic colorectal cancer. It was evaluated in a Phase 1 clinical trial in combination with chemotherapy for subjects with previously treated metastatic colorectal cancer. The drug is still in clinical development and is not approved by the FDA.
Brontictuzumab is being developed by Mereo BioPharma Group plc, a biopharmaceutical company. The company's stock is traded under the ticker symbol MREO. Mereo BioPharma is responsible for the clinical development of brontictuzumab for metastatic colorectal cancer.
Brontictuzumab is in Phase 1 clinical development. A Phase 1 study of brontictuzumab in combination with chemotherapy for metastatic colorectal cancer has been completed. The drug remains investigational and has not received FDA approval.
Brontictuzumab has been studied in one clinical trial, identified as NCT03031691. This was a Phase 1 study of brontictuzumab with chemotherapy for subjects with previously treated metastatic colorectal cancer. The trial was conducted in the United States and has been completed.
Brontictuzumab is not FDA approved. It is an investigational drug that has been evaluated in a Phase 1 clinical trial for metastatic colorectal cancer. The drug is still in clinical development and has not been approved for any use.